Neurointerventional Devices Market Size, Share & Trends Analysis Report By Product (Diagnostic Devices, Therapeutic Devices), By Indication (Acute Ischemic Stroke (AIS), Intracranial Aneurysm), By End Use, By Region, And Segment Forecasts, 2025 - 2033

Neurointerventional Devices Market Summary

The global neurointerventional devices market size was estimated at USD 2.95 billion in 2024 and is projected to reach USD 4.96 billion by 2033, growing at a CAGR of 5.9% from 2025 to 2033. The market is primarily driven by the rising prevalence of stroke, brain aneurysms, vascular malformations and other neurovascular disorders, coupled with the rapidly growing aging population prone to such conditions.

Increasing demand for minimally invasive procedures, which offer faster recovery and fewer complications than open surgery, further accelerates market growth. The rising incidence of neurological disorders such as stroke, aneurysms, and other neurovascular conditions is a key driver of the neurointerventional devices market, as it increases the demand for effective, minimally invasive treatments that can reduce disability, improve survival rates, and enhance patient outcomes. According to the World Federation of Neurology (WFN), neurological disease prevalence varies across age groups, including preterm, neonatal, childhood, adolescent, adult, and older adults who often experience age-related multimorbidity and frailty. The 2024 Global Burden of Disease study estimated that 43% of the world’s population is affected by a neurological disorder, underscoring the significant global demand for neurointerventional devices and treatments.

Technological advancements, including next-generation stent retrievers, flow diverters, and advanced imaging solutions, enhance treatment outcomes. Favorable regulatory approvals, improved reimbursement policies, and expanding healthcare infrastructure in emerging markets are supporting wider adoption of neurointerventional devices. For instance, in April 2024, Neurology journals have highlighted projections estimating that the number of brain disorder cases could reach 4.9 billion globally by 2050, marking a 22% increase compared to 2021. The all-age Disability-Adjusted Life Years (DALYs) rate of brain disorders is also expected to rise significantly by 10% globally, from 5,139 DALYs per 100,000 in 2021 to 5,666 DALYs per 100,000 in 2050. Headaches, Alzheimer’s disease, depressive and anxiety disorders, and strokes are identified as the primary contributors to this anticipated surge in prevalence and disease burden.

The rising incidence of stroke, particularly ischemic stroke is propelling the neurointerventional devices market by increasing the demand for efficient and minimally invasive clot removal procedures. For instance, in 2024, CDC data highlighted, as presented in the table below, that over 795,000 people in the U.S. suffer a stroke each year, emphasizing the growing need for advanced neurointerventional treatment options.[ According to the WHO, the global incidence of stroke is estimated to be approximately 15 million people annually, with ischemic stroke representing about 87% of all stroke cases.

According to the World Stroke Organization 2022, the table below shows the incidence and prevalence of ischemic stroke.

According to the Journal of Experimental Stroke & Translational Medicine, Hemorrhagic stroke accounts for approximately 10-15% of cases and results from the rupture of a blood vessel, causing bleeding within the brain tissue (intracerebral hemorrhage) or into the space surrounding the brain (subarachnoid hemorrhage).

Arteriovenous malformations (AVMs) are a significant factor driving the growth of the neurointerventional devices market, as these complex vascular abnormalities require precise and minimally invasive treatment approaches. The increasing detection of AVMs through advanced imaging techniques and the growing preference for endovascular procedures over open surgery fuel the demand for specialized neurointerventional devices such as embolization systems, catheters, and coils. Rising awareness among healthcare professionals about early intervention to prevent hemorrhagic complications further accelerates the adoption of advanced neurointerventional solutions for AVM management. According to a research article published by the National Center for Biotechnology Information, arteriovenous malformations (AVMs) are often asymptomatic in about 15% of cases until a clinical event occurs. Between 41% and 79% of AVMs are present with intracranial hemorrhage. They are the second most common cause of intracranial bleeding after cerebral aneurysms, accounting for approximately 10% of all subarachnoid hemorrhages.

The growing aging population drives the neurointerventional devices market, as older adults are more prone to neurovascular conditions such as stroke, aneurysms, and age-related cerebrovascular diseases. This demographic trend increases the demand for minimally invasive interventions and advanced neurovascular devices. For instance, in June 2024, the Brain Aneurysm Foundation reported that an estimated 6.8 million people in the United States, about 1 in 50, have an unruptured brain aneurysm, with an annual rupture rate of 8-10 per 100,000 people. Each year, roughly 30,000 Americans experience a brain aneurysm rupture, which occurs on average every 18 minutes. Globally, brain aneurysms cause nearly 500,000 deaths annually, with half of the victims under 50. While most aneurysms develop after age 40 and are most common between ages 35 to 60, they can also occur in children. Women are more likely than men to have a brain aneurysm (3:2 ratio), and women over 55 faces approximately 1.5 times higher risk of rupture than men.

Global Neurointerventional Devices Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global neurointerventional devices market report based on product, indication, end use, and region:

• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Diagnostic Devices
• Catheters
• Distal Access Catheters
• Microcatheters
• Others
• Guidewires
• Imaging Systems
• Therapeutic Devices
• Embolic Materials
• Embolic Coils
• Embolic Agents
• Neurovascular Stents
• Self-Expanding Stents
• Balloon-Expandable Stents
• Flow Diverter Stents
• Coil-Assist Stents
• Neurothrombectomy Devices
• Intrasaccular Devices
• Embolic Protection Devices
• Others
• Indication Outlook (Revenue, USD Million, 2021 - 2033)
• Acute Ischemic Stroke (AIS)
• Intracranial Aneurysm
• Cerebral Arterial Stenosis
• Arteriovenous Malformation (AVM)
• Spinal Vascular Malformations
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Hospitals
• Specialty Clinics
• Ambulatory Surgery Centers
• Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
• U.S.
• Canada
• Mexico
• Europe
• UK
• Germany
• France
• Italy
• Spain
• Denmark
• Sweden
• Norway
• Asia Pacific
• Japan
• China
• India
• Australia
• Thailand
• South Korea
• Latin America
• Brazil
• Argentina
• Middle East & Africa
• South Africa
• Saudi Arabia
• Kuwait
• UAE

Please note The report will be delivered in 4-8 business days upon order notification. Show more